<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2925">
  <stage>Registered</stage>
  <submitdate>24/09/2010</submitdate>
  <approvaldate>24/09/2010</approvaldate>
  <nctid>NCT01209650</nctid>
  <trial_identification>
    <studytitle>LUX Lung Special Access Scheme Australia Named Patient Use (NPU)</studytitle>
    <scientifictitle>Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1200.47</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma, Non-Small-Cell Lung</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BIBW 2992

Treatment: drugs: BIBW 2992
tablets

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Patients with pathologic confirmation of adenocarcinoma of the lung Stage IIIB with
             pleural effusion or Stage IV</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Brain metastases which are symptomatic; patients with treated, asymptomatic brain
             metastases are eligible with stable brain disease for at least four 4 weeks without
             the requirement for steroids or anti epileptic therapy

          -  Significant or recent acute gastrointestinal disorders with diarrhea as a major
             symptom as judged by the investigator.

          -  Patients who have any other life-threatening illness or organ system dysfunction,
             which in the opinion of the investigator, would either compromise patient safety or
             interfere with the evaluation of the safety of the test drug

          -  History of cardiac disease that is clinically significant, as judged by the
             investigator or uncontrolled cardiac disease (including congestive heart failure,
             angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA)
             functional classification of 3)

          -  Cardiac left ventricular function with resting ejection fraction of less than 50%

          -  Bilirubin 1.5 mg / dl (26 mol / L, SI unit equivalent)

          -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) three times the
             upper limit of normal (if related to liver metastases five times the upper limit of
             normal)

          -  Serum creatinine 1.5 times of the upper normal limit or calculated/measured creatine
             clearance 45ml/min

          -  Women of child-bearing potential or men who are able to father a child unwilling to
             use a medically acceptable method of contraception during the trial

          -  Pregnancy or breast feeding

          -  Patients unable to comply with the protocol

          -  Patients with known HIV, active hepatitis B or active hepatitis C

          -  Pre-existing Interstitial Lung Disease (ILD)

          -  Requirement for treatment with any of the prohibited concomitant medications listed in
             Section 4.2.2.1.

          -  Patients already pre-treated with BIBW 2992</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Expanded Access</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Approved for marketing</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>1200.47.1 Boehringer Ingelheim Investigational Site - North Ryde</hospital>
    <postcode> - North Ryde</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The program will provide early access to the investigational drug BIBW 2992 to treat patients
      with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.

      The Compassionate Use Programme will also provide additional safety and efficacy information
      on BIBW 2992 use.

      Named Patient Use (NPU)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01209650</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>